Wranglers Trading Zone

[wrangler]

TMTA : bought today @1.30. After studing chart I feel this stock will be heading back up. I'm not bottom fishing I like how the candle's has formed since the huge buying that happened 6 trading day's ago.If it can make it above 1.35 and stay then I think a new uptrend will start. I'll be looking to put a stop loss in @1.21 in case it doesn't go as planed.
Goodluck trading
Still holding
SNUS
EGHT
ARBA

GO,,GO,,GO,GGGGOOOO BREAKOUT TMTA,,tomorrow will be OK if it doesn't happen today

[wrangler]

ARBA : looks to have some trader's taking some off the table today before earning's.Will be watching it close but I think it will run higher before earning's get's here

The day was interesting watching ARBA as the day went before earning's release. Thought maybe it might hold and begin to trade above 9.00 but when I seen it started to fall I decided to sell @ 8.71 then it ended at 9.00 for the day and thought maybe I made a mistake till I seen after hour's trading when I got home from work and seen it @8.35 now I think I made the right decision. It had a bad report. I should have sold @9.00 when I had the chance but still happy with where I sold it. Was bought @8.3199 on 10-05-06 The previous page will show where I entered if you want to see where I first posted on it.
Sorry for not keeping thread as active as I would like but I've been busy. This weekend I'll try to update it.
Since my last update I have added three more positions

GNVC @1.69 on 10-24-06
ZIXI @1.20 Not for sure about buy date on this one I will update it this weekend
Stll holding
SNUS
EGHT
TMTA

Forgot to post chart on GNVC when I first bought it . It is stated above and since then it had fallen but I held because sell signal had not been hit and glad I did hold. I'm looking for it to make breakout now. Here is some new's and check out chart for today.

Public release date: 10-Nov-2006
[ Print Article | E-mail Article | Close Window ]

Contact: Steve Baragona
[email protected]
703-299-0412
Infectious Diseases Society of America

Progress made in HIV vaccine development
Researchers have successfully tested two candidate vaccines that may eventually be used together to confer immunity against HIV infection. Their findings are published in the December 15 issue of The Journal of Infectious Diseases, now available online.

Barney S. Graham, MD, PhD, and colleagues from the National Institutes of Health IH Vaccine Research Center in Maryland, the Fred Hutchinson Cancer Research Center in Seattle, and GenVec Incorporated tested two possible HIV vaccines with the hope of producing an immune response in healthy, uninfected adults. One was a plasmid DNA-based vaccine expressing genes from three dominant HIV subtypes, and the second used recombinant adenovirus serotype 5 (rAd5) as a vector to deliver similar HIV strains.

"Both approaches operate by gene delivery of customized vaccine antigens that are produced by host cells to initiate an immune response. DNA is simple and does not have the problem of anti-vector immunity. However, DNA may be less potent than vector-based gene delivery strategies. Replication-defective rAd5 has the advantage of targeted, efficient gene delivery and high potency, but may be susceptible to anti-vector immunity," said Graham.

Both vaccines were tested in healthy uninfected adult volunteers. The DNA vaccine was found safe and well-tolerated. By week 12 following immunization, 97.5% of vaccinees experienced positive CD4 T cell responses and 40% experienced positive CD8 T cell responses.

The recombinant vector vaccine was also well-tolerated, but higher doses led to some adverse events such as pain and fever. By week 4 following immunization, 93.3% of vaccinees experienced positive CD4 T cell responses, and 60% experienced positive CD8 T cell responses.

"HIV-specific CD8 cell responses clear virus infected cells, and appear during the declining viremia following acute infection," explained Graham. "HIV-specific CD4 responses also peak early in infection; however this response diminishes soon after seroconversion. Maintenance of a functional HIV-specific CD4 T cell response correlates with long term non-progression of HIV disease."

Harriet L. Robinson, PhD, from Emory University and Kent J. Weinhold, PhD, from Duke University commented on the impact of these results in their accompanying editorial. "The DNA studies are a landmark for DNA-based vaccines in that they are the first to demonstrate a DNA vaccine successfully eliciting immune responses in essentially all vaccinated volunteers," they said. "The Ad5 recombinant HIV vaccine had both a higher percentage of responders and, overall, a higher magnitude of responses than the DNA vaccine."

The next step, according to Graham, is "to evaluate the combination of DNA priming and rAd5 boosting. Combining these distinct gene-delivery vaccination approaches has the potential to induce higher levels of T cell responses and a different quality of response than either approach by itself."

As Robinson and Weinhold add, the idea behind combining strategies is that "the vaccine uses DNA to prime the immune response and a replication defective recombinant adenovirus serotype 5 vector to boost responses."
###
Founded in 1904, The Journal of Infectious Diseases is the premier publication in the Western Hemisphere for original research on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune mechanisms. Articles in JID include research results from microbiology, immunology, epidemiology, and related disciplines. It is published under the auspices of the Infectious Diseases Society of America (IDSA). Based in Alexandria, Va., IDSA is a professional society representing nearly 8,000 physicians and scientists who specialize in infectious diseases. Nested within the IDSA, the HIV Medicine Association (HIVMA) is the professional home for more than 2,600 physicians, scientists and other health care professionals dedicated to the field of HIV/AIDS. HIVMA promotes quality in HIV care and advocates policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice.

[wrangler]

While posting article about GNVC I noticed ZIXI below it. It's hard to keep up with all the buy and sell sometime's.
ZIXI I sold on 11-13-06 @1.12 for a loss after my I bought on 10-24-06 @1.20 I was sure of it trending higher but it started falling and when it hit 1.00 I was mad at myself for not selling before it got that low,," so important to use stop losses " and when it climbed back up on 11-13-06 I sold @1.12 which is my 8% sell loss I'm trying to make a rule for my trading.
But selling it resuled in two Losses the loss I took when I sold @1.12 and the loss I now would be gaining if I held it is now @1.41. Man you talk about getting hit bad twice in one week and now I'm lossing big on POTP bought on 10-31-06 @1.46 and is now trading around 1.00.
Three big hit's in one week. I'm still holding POTP figure now what the heck I'm going to hold forever if I half to to at least break even on it.

By the way ZIXI is in breakout mod,,check out chart

[wrangler]

Three stock's I'm trying to grab in after hour's trading,,if any doesn't get filled will try again in the morning
CLWT @2.56
ACAM @3.94
MRVC @3.30

Decided not to buy any of these and decided to buy
MOT @22.45 today

Check out after hour's trading..one trade of 1,375,000 shares @22.61
 
   After Hours Trade Reporting   
   

After Hours
Last: $ 22.43   After Hours
High: $ 22.80 
After Hours
Volume: 1,383,500   After Hours
Low: $ 22.43

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18:55   $ 22.43  300
18:45   $ 22.60  1,500
18:41   $ 22.61  500
18:17   $ 22.61  200
17:56   $ 22.61  100
17:54   $ 22.61  100
17:19   $ 22.61  100
17:08   $ 22.66  100
17:08   $ 22.64  200
17:08   $ 22.61  100
17:08   $ 22.61  100
17:08   $ 22.61  200
17:05   $ 22.61  1,375,000
17:05   $ 22.70  100
16:19   $ 22.61  1,000
16:04   $ 22.61  100
16:04   $ 22.61  1,700
16:03   $ 22.80  100
16:03   $ 22.61  2,000



 



1 

[wrangler]

AGN : will be interesting to see how much higher it will go after today's new's of FDA approval of Silicone Gel-Filled Breast Implants
FDA News
FOR IMMEDIATE RELEASE
P06-189
November 17, 2006
Media Inquiries:
Heidi Valetkevitch, 301-827-6242
Consumer Inquiries:
888-INFO-FDA

FDA Approves Silicone Gel-Filled Breast Implants
After In-Depth Evaluation
Agency Requiring 10 Years of Patient Follow-Up
After rigorous scientific review, the U.S. Food and Drug Administration (FDA) today approved the marketing of silicone gel-filled breast implants made by two companies for breast reconstruction in women of all ages and breast augmentation in women ages 22 and older.  The products are manufactured by Allergan Corp. (formerly Inamed Corp.), Irvine, Calif., and Mentor Corp., Santa Barbara, Calif.

"FDA has reviewed an extensive amount of data from clinical trials of women studied for up to four years, as well as a wealth of other information to determine the benefits and risks of these products," said Daniel Schultz, M.D., Director, Center for Devices and Radiological Health, FDA.  "The extensive body of scientific evidence provides reasonable assurance of the benefits and risks of these devices.  This information is available in the product labeling and will enable women and their physicians to make informed decisions."

Now that the products have been determined to be safe and effective, FDA will continue to monitor them by requiring each company to conduct a large postapproval study following about 40,000 women for 10 years after receiving breast implants.  FDA often requires postmarket studies to answer important questions that can only be answered once a product is in broader use, such as the incidence of rare adverse events. 

FDA's decision to approve these implants was based on a thorough review of each company's clinical (core) and preclinical studies, a review of studies by independent scientific bodies and deliberations of advisory panels of outside experts that heard public comment from hundreds of stakeholders.  In addition, FDA conducted inspections of each company's manufacturing facilities to determine that they comply with FDA's Good Manufacturing Practices.  Some of the complications reported in the core studies included hardening of the area around the implant, breast pain, change in nipple sensation, implant rupture and the need for additional surgery.  However, the majority of women in these studies reported being satisfied with their implants. 

In the past decade, a number of independent studies have examined whether silicone gel-filled breast implants are associated with connective tissue disease or cancer.  The studies, including a report by the Institute of Medicine, have concluded there is no convincing evidence that breast implants are associated with either of these diseases.  However, these issues will be addressed further in the postapproval studies conducted by the companies.

"The silicone breast implant is one of the most extensively studied medical devices," said Schultz.  "We now have a good understanding of what complications can occur and at what rates.  We also know that women who get these devices will probably need to have additional breast implant surgery at least once.  This is valuable information for women who may be considering these products."

Full information about the risks and benefits of the devices can be found in the package and patient labeling mandated by FDA.  The patient labeling outlines some of the important factors women should consider when deciding whether to get silicone gel-filled breast implants.  Some of these factors are: breast implants are not lifetime devices and a woman will likely need additional surgeries on her breast at least once over her lifetime; many of the changes to a woman's breast following implantation are irreversible; rupture of a silicone gel-filled breast implant is most often silent, which means that usually neither the woman nor her surgeon will know that her implants have ruptured; and a woman will need regular screening MRI examinations over her lifetime to determine if silent rupture has occurred.  The device labeling states that a woman should have her first MRI three years after her initial implant surgery and then every two years thereafter.  The cost of MRI screening over a woman's lifetime may exceed the cost of her initial surgery and may not be covered by medical insurance.  The labeling also states that if implant rupture is noted on an MRI, the implant should be removed and replaced, if needed.

FDA approved the silicone gel-filled breast implants with a number of conditions, including requiring each company to: conduct a large postapproval study; continue its core study through 10 years; conduct a focus group study of the patient labeling; continue laboratory studies to further characterize types of device failure; and track each implant in the event, for example, that health professionals and patients need to be notified of updated product information.

The postapproval studies will continue to gather information about the safety and effectiveness of the implants.  Information will be collected about rates of local complications, rates of connective tissue disease and its signs and symptoms, rates of neurological disease and its signs and symptoms, potential effects on offspring of women with breast implants, potential effects on reproduction and lactation, rates of cancer, rates of suicide, potential interference of breast implants with mammography, and MRI compliance and rupture rates. 

The postapproval studies will be closely monitored by FDA.  FDA anticipates that data from the studies will provide important information for patients and physicians, and may lead to improvements in device labeling.

[wrangler]

IVAN : buy signal was given Friday,bounced up off two month support and is ready to move up with two target's to shoot for. First one is resistance between @ 1.50 and 1.55 second one is between resistance @1.65 and 1.70
I'm not entering this position,,have no fund's available right now but think this would be a good opportunity for a good trade to enter. Remember to alway's use stop losses,,a lesson I have recently learned again. Sometimrs you get to confident trading and relax on putting stop losses in and get burned.

[wrangler]

TVIN : look's ready to retest previous resistance

[wrangler]

PMCS : I'm posting chart that show's two possible play's that could make you some cash if you play this plan be sure to do you're own TA before entering. One play is a possible breakout but with any breakout alway's check volume to confirm investor's is interested in it. If breakout doesn't happen wait for pullback to previous support to enter and set stop loss right below where it is shown on chart and wait for it to hit resistance or stop loss to be hit.
So far now for two month's it's been trading within the sideway's trend that has formed and could make you some cash.
Any comment's is welcomed
Goodluck trading tomorrow

updating some of my alert's I have posted
PMCS has done good since I first put alert out on it. It was @6.93 when first post was added and is now @7.80 and has had a high 0f 8.25 three day's ago. It seem's to be in consolidation right now. Now would be a bad time to enter it might pull back to 7.50 at which time I'm thinking it will bounce back . 

[wrangler]

GERN : look's ready to make the coiled spring effect
MVIS : is one to watch

No chart's added for these,,sorry, using dial modem for now and it's to slow when house is done being built I'll have broadband then and will do better on update's
GERN : was 8.48 when first posted,, closed Friday @8.75 and a high of 9.00 since post was added
MVIS :was 3.24 when first posted and is now @2.63 but has had a high of 3.45 since posted and look's like it might be getting ready for bounce back up

[wrangler]

RIO : put this one on you're watchlist for tomorrow

Companhia Vale Do Rio Doce Posts Higher Q3 Net Earnings As Revenues Increase - Update [RIO]

11/8/2006 8:06:26 PM Wednesday, Companhia Vale do Rio Doce (RIO), a metals and mining company, announced third quarter earnings that rose year-over-year on higher sales.

The Rio de Janeiro, Brazil headquartered company said net earnings, for the third quarter of 2006 rose 44.6% to US$ 1.9 billion, or US$ 0.79 per share compared to the third quarter of 2005. On average, 4 analysts surveyed by First Call/Thomson Financial expected the company to earn $0.68 per share for the quarter. The company said operational profit as measured by adjusted earnings before interest and taxes reached US$ 2.2 billion, a 60% increase over third quarter 2005. Cash flow as measured by adjusted earnings before interest, taxes, depreciation and amortization was US$ 2.7 billion, nearly US$1 billion higher than in third quarter of 2005.

The company said gross revenue for the third quarter of 2006 amounted to US$ 5.1 billion, 17.5% above the US$ 4.3 billion in second quarter of 2006. 3 analysts had a revenue consensus opinion of $4.64 billion for the quarter.

The company said that the Brucutu project, an asset with nominal iron ore production capacity of 30 Mtpy, started operating in third quarter 2006. Simultaneously, the expansion of Carajas iron ore capacity to 85 Mtpy came on stream. Sales volume records in iron ore and pellets 73.4 million tons and potash 291 thousand tons.

The company said in the first nine months of 2006 net earnings totaled US$ 5.0 billion, or US$ 2.04 per share. Operational profit as measured by adjusted earnings before interest and taxes reached US$ 5.5 billion for the first nine months of this year. Revenue between January and September 2006 was US$ 12.9 billion, a 33.2% increase over the same period last year.

RIO closed Wednesday's regular trading session at $26.91

RIO : Bad call on this one next trading day it had a high of 28.05 and alert price was 26.91 even though it look good for a while it formed an Island top which is alway's a sign of a stock getting ready to fall if the next day's trading didn't touch it ,,it would have been a perfect island top and would have been a perfect short signal. It is now @ 26.05 and hit my sell signal with next support @25.00 but I would stay away from this one because of the Island top that was formed

[wrangler]

BAS : another one to watch

Basic Energy Services Q3 Earnings More Than Double - Quick Facts [BAS]

11/8/2006 8:05:54 PM Basic Energy Services, Inc. (BAS) reported third quarter net income of $27.3 million or $0.71 per share, compared to $12.3 million or $0.37 per share in the same period in 2005. On average, 8 analysts polled by First Call/Thomson Financial expected the company to earn $0.73 per share for the quarter.

Quarterly revenues rose 61% to $194.6 million from $120.8 million in the prior year quarter. The substantial year-over-year increase in revenue was driven primarily by acquisitions completed and new equipment added over the course of the year. Analysts had revenue consensus estimate of $197.07 million for the quarter.

BAS : very bad call it showed all sign's of a new uptrend but next day after alert @26.28 it has fallen all the way back to 9 month support @22.34 which might make it a good time to enter

[wrangler]

Good job in the "Wrangler's trading zone" !
I have been keeping an eye on this section.... 
Applaud the work..... 

Thank's setravis

PSUN you might want to put this one on you're watchlist
Was upgraded to outperform today and caused a jump if you decide to enter wait for pullback from spike caused by upgrade, Find most recent support for entry when hit

PSUN : alert was given @18.56 and now @18.92 and ahigh since first alert @19.50 it might be getting ready to fill the gap but I look for this to bounce back up when it does or could possibly jump without filling gap. Still nowhere close to my sell signal but buy signal was given when gap was made. Would advise to sell and be prepared to re-enter when bounce happens just in case gap is being filled

[wrangler]

ADPT : I'm trying to grab some on pre-market @4.45 if it doesn't go thru will decide after one hour of trading if I want to enter. Will post result's later

Adaptec Launches a New Family of Entry-Level Serial ATA Controllers for the PCI-Express Interconnect
Market Wire (Tue 8:30am) 
• The Market's 10 Worst Stocks
at Motley Fool (Thu, Nov 9) 
• ADAPTEC INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Wed, Nov  
• Adaptec Launches iSCSI Storage Software Solution
Market Wire (Tue, Oct 31) 
• Adaptec posts first profit since 2004
bizjournals.com (Mon, Oct 30) 
• Adaptec posts Q2 profit
at Reuters (Mon, Oct 30) 

This will be my last update tonight.
ADPT : I didn't get order filled @4.45 and now it's @4.60 and has had a high of 4.68. It is now been testing resistance and looks like it might break it with how trading has been going for the last 5 trading day's. Buy signal was given ,,I'm think it's getting ready to move up

Stock's I'm now holding
MOT : buy price @22.45 on 11-16-08
POTP : buy price @1.46 and is performing terrible is now @0.92 I think I was fished in on a pump and dump. I like to buy on the way up but this stock came out with some good new's when it caused a spike up and I wanted to get in early ,,,BIG mistake I should have waited for the run. I'm going to continue to hold
GNVC : buy price @1.69 on 10-24-06
TMTA : buy price @1.30 on 10-19-06
Goodluck trading to all

[wrangler]

AGN : will be interesting to see how much higher it will go after today's new's of FDA approval of Silicone Gel-Filled Breast Implants
FDA News
FOR IMMEDIATE RELEASE
P06-189
November 17, 2006
Media Inquiries:
Heidi Valetkevitch, 301-827-6242
Consumer Inquiries:
888-INFO-FDA

FDA Approves Silicone Gel-Filled Breast Implants
After In-Depth Evaluation
Agency Requiring 10 Years of Patient Follow-Up
After rigorous scientific review, the U.S. Food and Drug Administration (FDA) today approved the marketing of silicone gel-filled breast implants made by two companies for breast reconstruction in women of all ages and breast augmentation in women ages 22 and older.  The products are manufactured by Allergan Corp. (formerly Inamed Corp.), Irvine, Calif., and Mentor Corp., Santa Barbara, Calif.

"FDA has reviewed an extensive amount of data from clinical trials of women studied for up to four years, as well as a wealth of other information to determine the benefits and risks of these products," said Daniel Schultz, M.D., Director, Center for Devices and Radiological Health, FDA.  "The extensive body of scientific evidence provides reasonable assurance of the benefits and risks of these devices.  This information is available in the product labeling and will enable women and their physicians to make informed decisions."

Now that the products have been determined to be safe and effective, FDA will continue to monitor them by requiring each company to conduct a large postapproval study following about 40,000 women for 10 years after receiving breast implants.  FDA often requires postmarket studies to answer important questions that can only be answered once a product is in broader use, such as the incidence of rare adverse events. 

FDA's decision to approve these implants was based on a thorough review of each company's clinical (core) and preclinical studies, a review of studies by independent scientific bodies and deliberations of advisory panels of outside experts that heard public comment from hundreds of stakeholders.  In addition, FDA conducted inspections of each company's manufacturing facilities to determine that they comply with FDA's Good Manufacturing Practices.  Some of the complications reported in the core studies included hardening of the area around the implant, breast pain, change in nipple sensation, implant rupture and the need for additional surgery.  However, the majority of women in these studies reported being satisfied with their implants. 

In the past decade, a number of independent studies have examined whether silicone gel-filled breast implants are associated with connective tissue disease or cancer.  The studies, including a report by the Institute of Medicine, have concluded there is no convincing evidence that breast implants are associated with either of these diseases.  However, these issues will be addressed further in the postapproval studies conducted by the companies.

"The silicone breast implant is one of the most extensively studied medical devices," said Schultz.  "We now have a good understanding of what complications can occur and at what rates.  We also know that women who get these devices will probably need to have additional breast implant surgery at least once.  This is valuable information for women who may be considering these products."

Full information about the risks and benefits of the devices can be found in the package and patient labeling mandated by FDA.  The patient labeling outlines some of the important factors women should consider when deciding whether to get silicone gel-filled breast implants.  Some of these factors are: breast implants are not lifetime devices and a woman will likely need additional surgeries on her breast at least once over her lifetime; many of the changes to a woman's breast following implantation are irreversible; rupture of a silicone gel-filled breast implant is most often silent, which means that usually neither the woman nor her surgeon will know that her implants have ruptured; and a woman will need regular screening MRI examinations over her lifetime to determine if silent rupture has occurred.  The device labeling states that a woman should have her first MRI three years after her initial implant surgery and then every two years thereafter.  The cost of MRI screening over a woman's lifetime may exceed the cost of her initial surgery and may not be covered by medical insurance.  The labeling also states that if implant rupture is noted on an MRI, the implant should be removed and replaced, if needed.

FDA approved the silicone gel-filled breast implants with a number of conditions, including requiring each company to: conduct a large postapproval study; continue its core study through 10 years; conduct a focus group study of the patient labeling; continue laboratory studies to further characterize types of device failure; and track each implant in the event, for example, that health professionals and patients need to be notified of updated product information.

The postapproval studies will continue to gather information about the safety and effectiveness of the implants.  Information will be collected about rates of local complications, rates of connective tissue disease and its signs and symptoms, rates of neurological disease and its signs and symptoms, potential effects on offspring of women with breast implants, potential effects on reproduction and lactation, rates of cancer, rates of suicide, potential interference of breast implants with mammography, and MRI compliance and rupture rates. 

The postapproval studies will be closely monitored by FDA.  FDA anticipates that data from the studies will provide important information for patients and physicians, and may lead to improvements in device labeling.

Two stock's to watch for today
AGN
SOMX

Somaxon Pharmaceuticals Is Heading Higher On Phase 3 Results [SOMX]

11/20/2006 9:08:15 AM Somaxon Pharmaceuticals (SOMX) announced positive results from its Phase 3 clinical trial evaluating SILENOR in elderly patients with primary sleep maintenance insomnia, Monday morning. The drug demonstrated a statistically significant improvement compared to placebo in the primary endpoint of the trial, subjective Total Sleep Time as measured at week one, and was maintained for all timepoints measured throughout the 4-week treatment period. Somaxon is now trading higher by 1.46 on 18K shares.

Somaxon Pharmaceuticals is a thinly traded stock that was range-bound for the bulk of Friday's session and closed up by 0.34 at $14.49. The stock closed near the middle of a 3 1/2 week range.

[wrangler]

Have decided to start thread again after being absent for a while. Have noticed many new members and have enjoyed reading many of their post.
Since being gone I can say from being a subscribed member to nonsubscribed member that I'm still impressed by how this site is handled by the site owners.
David & Ramsburg has truly given the investor that comes here and stays the upper advantage when it comes to stock trading along with some of the best TA you can get anywhere from some of the best teachers that this site has from its members. If you cann't learn it here then you're never going to learn it because it doesn't get any better than this.

Wishing everyone here a great trading day and may it continue for the rest of the year


For now I'm keeping my trading on low profile. Will post buy and sell trading plans later as time allows.
Two stocks I'll post is one penny and one major exchange that I now hold
WTVI : penny that I've played once and now trying again.
CBRX : catching a falling knife